SynthesisMedical mycology2024
Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Synthesis in Medical mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Hyptolactones and Their Biological Potential: A Systematic Review.Journal of natural products · 2025Pooled it
- Efficacy of probiotics for oral candidiasis management: a systematic review.BMC oral health · 2025Pooled it
- Genomic features, metabolism, and biotechnological applications of Candida tropicalis and other non-albicans Candida species.World journal of microbiology & biotechnology · 2026Review
- Epidemiology, Diagnostics and Therapy of Vulvovaginal Fungal Infections.Pathogens (Basel, Switzerland) · 2026Review
- Molecular mechanisms and therapeutic perspectives in vulvodynia: From current evidence to future investigations.Cell reports. Medicine · 2026Review
- Morphotype-specific susceptibility toMicrobiology spectrum · 2026Article
- Expansion, functional diversification, and gene fusion events in the Ato protein family.iScience · 2026Article
- A Cationic Supramolecule With Potent Antifungal Activity, Single-Species Selectivity, and Strong Synergy With Echinocandins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Gut microbiota and immune modulation: role in neurodegenerative disorders and cancer.Molecular biology reports · 2026Review
- C-BODIPY Dyads Based on Fused-Ring Organoboron Scaffolds for Efficient Photodynamic Therapy TargetingJournal of medicinal chemistry · 2026Article
- Atypical cutaneous candidiasis mimicking tinea corporis in an otherwise healthy young man: A case report.Medical mycology case reports · 2026Article
- Biofilm formation efficiency by Candida species isolated from gastric mucosa of intragastric balloon patient under extremely low pH.Folia microbiologica · 2026Article
- Anti-Candida albicans effect of the new antifungal compound Venetin-1 obtained from earthworms versus amphotericin B.Scientific reports · 2026Article
- Epidemiological and genotypic analysis of Candida albicans outbreak in a neonatal ward.BMC infectious diseases · 2026Article
- Incidence and characteristics of candidemia in hospitalised patients with advanced HIV in the Médecins Sans Frontières (MSF) hospital in Kinshasa, Democratic Republic of Congo (DRC).AIDS research and therapy · 2026Article
- Ferric reductase related proteins Frp1 and Frp2 mediate reductive heme uptake in the opportunistic pathogen Candida albicans.Journal of inorganic biochemistry · 2026Article
- Integrative in vitro and in silico assessment of bicyclic monoterpenes as antifungal agents targeting the cell membrane integrity of Candida albicans.Archives of microbiology · 2026Article
- Article
- EditingBiomolecules · 2026Review
- Species Identification, Virulence Factors, and Antifungal Resistance in ClinicalMicroorganisms · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
Abstract
Candida albicans is a common fungal pathogen and amongst the leading causes of invasive candidiasis globally. This systematic review examines the characteristics and global impact of invasive infections caused by C. albicans. We searched on PubMed and Web of Science for studies reporting on criteria such as mortality, morbidity, drug resistance, preventability, yearly incidence, and distribution/emergence during the period from 2016 to 2021. Our findings indicate that C. albicans is the most common Candida species causing invasive disease and that standard infection control measures are the primary means of prevention. However, we found high rates of mortality associated with infections caused by C. albicans. Furthermore, there is a lack of data on complications and sequelae. Resistance to commonly used antifungals remains rare. Although, whilst generally susceptible to azoles, we found some evidence of increasing resistance, particularly in middle-income settings-notably, data from low-income settings were limited. Candida albicans remains susceptible to echinocandins, amphotericin B, and flucytosine. We observed evidence of a decreasing proportion of infections caused by C. albicans relative to other Candida species, although detailed epidemiological studies are needed to confirm this trend. More robust data on attributable mortality, complications, and sequelae are needed to understand the full extent of the impact of invasive C. albicans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.